Syros Pharmaceuticals, which is developing small-molecule genetic therapies targeting leukemia, announced terms for its IPO on Monday.
The Cambridge, MA-based company plans to raise $60 million by offering 4 million shares at a price range of $14 to $16. Insiders intend to purchase $35 million worth of shares in the offering. At the midpoint of the proposed range, Syros Pharmaceuticals would command a fully diluted market value of $363 million.
Syros Pharmaceuticals was founded in 2011 and plans to list on the Nasdaq under the symbol SYRS. Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of June 27, 2016.
